

Table 1. Patient Characteristics at Study Enrollment

Characteristic	All patients (n = 387)	Patients with eye involvement (n = 154)
Patient median age, y (range)	51 (2-79)	51 (11-79)
Median time from transplant to enrollment, months (range)	12.3 (2.9-39.2)	13.1 (3.5-36.2)
Median time from onset of chronic GVHD to enrollment, months (range)	2.4 (0-35.3)	4.3 (0-30.3)
Patient gender, no. (%)		
Male	226 (58)	84 (55)
Female	161 (42)	70 (45)
Type of enrollment, no. (%)		
Incident	209 (54)	71 (46)
Prevalent	178 (46)	83 (54)
Diagnosis at transplant, no. (%)		
Acute myeloid leukemia	128 (33)	53 (34)
Acute lymphoblastic leukemia	51 (13)	23 (15)
Chronic myeloid leukemia	19 (5)	7 (5)
Chronic lymphocytic leukemia	27 (7)	6 (4)
Myelodysplastic syndrome	55 (14)	32 (21)
Malignant lymphoma	72 (19)	22 (14)
Multiple myeloma	20 (5)	8 (5)
Aplastic anemia	5 (1)	1 (1)
Other	10 (3)	2 (1)
Graft type, no. (%)		
Bone marrow	29 (7)	7 (5)
G-CSF-mobilized peripheral blood	341 (89)	140 (90)
Cord blood	17 (4)	7 (5)
Donor-patient gender combination, no. (%)		
Female to male	108 (28)	44 (29)
Other	279 (72)	110 (71)
HLA and donor type, no. (%)		
HLA-matched relative	175 (45)	75 (49)
HLA-mismatched relative	8 (2)	1 (1)
Unrelated volunteer	204 (53)	78 (50)
Conditioning regimen, no. (%)		
Myeloablative	217 (56)	93 (60)
Non-myeloablative / reduced-intensity	170 (44)	61 (40)
Center, no. (%)		
Fred Hutchinson Cancer Research Center	186 (49)	57 (37)
Stanford University Medical Center	55 (14)	30 (19)
Dana-Farber Cancer institute	47 (12)	23 (15)
University of Minnesota	44 (11)	23 (15)
Vanderbilt University Medical Center	31 (8)	12 (8)
Northwestern Children's	13 (3)	3 (2)
Medical College of Wisconsin	11 (3)	6 (4)

Table 1. (Continued)

Characteristic	All patients (n = 387)	Patients with eye involvement [*] (n = 154)
Prior history of acute GVHD, no. (%)		
Present	258 (67)	98 (64)
Absent	129 (33)	56 (36)
Organ involvement of chronic GVHD [†] , no. (%)		
Skin	241 (62)	84 (55)
Mouth	237 (61)	113 (73)
Eye	191 (49)	154 (100)
Gastrointestinal tract	112 (29)	48 (31)
Liver	196 (51)	87 (57)
Lung	194 (50)	84 (55)
Joint and fascia	113 (29)	45 (29)
Genital tract	41 (12)	16 (12)
Severity of NIH eye score, no. (%)		
Score 0	196 (50)	0 (0)
Score 1	119 (31)	87 (57)
Score 2	62 (16)	57 (37)
Score 3	10 (3)	10 (6)
Measurement scale score		
NIH eye score		
Median (range)	0 (0-3)	1 (1-3)
Mean (SD)	0.7 (0.8)	1.5 (0.6)
Patient-reported global rating of eye symptoms		
Median (range)	2 (0-10)	5 (0-10)
Mean (SD)	3.2 (3.0)	5 (2.8)
Eye subscale of Lee symptom scale		
Median (range)	25 (0-100)	58.3 (12.5-100)
Mean (SD)	34.8 (30.2)	57.4 (26.2)
Ocular surface disease index (OSDI)		
Median (range)	11.4 (0-95.8)	22.9 (0-95.8)
Mean (SD)	18.5 (20.0)	29.2 (21.5)
Schirmer score for the worst eye		
Median (range)	10 (0-35)	5 (0-35)
Mean (SD)	11.9 (9.9)	7.4 (7.6)

GVHD = graft-versus-host disease; NIH = National Institutes of Health; SD = standard deviation.

^{*}Eye involvement was reported by both the clinician and the patient.

[†]Involvement was defined as NIH severity score greater than zero.